anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study is an open-label evaluation of treatment with tipifarnib in approximately 127 subjects, 60 years and older, with AML in complete remission (CR) after consolidation therapy. Prior to enrollment, patients will receive 1 or 2 cycles of induction chemotherapy. Patients who attain a CR will receive 1 or 2 cycles of consolidation chemotherapy. Patients in postconsolidation complete remission who meet the eligibility criteria are offered enrollment in the study. Subjects enrolled in the study are treated with tipifarnib A dose-modification scheme is followed to maintain adequate specified laboratory values and to minimize other adverse events. Postconsolidation treatment with tipifarnib continues until the time of relapse, death, completion of 24 cycles of treatment, or discontinuation as advised by study doctor.

Tipifarnib, film coated, compressed tablets containing 100 mg active drug, will be administered orally at a dose of 300 mg (three 100 mg film coated tablets) taken twice a day for 21 consecutive days on a 28-day cycle schedule for up to 24 months.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry and deals with medication, obtained by interaction of selenium-containing compound with alpha, alpha-dichlorcarboxylic acid, stabilised by nitric acid in amount not more than 5 wt %. As selenium-containing compound in interaction used is solution of selenious acid in amount not more than 20.0 wt %. Medication can additionally contain dimethylsulfoxide in amount 5-20%. Method of obtaining medication is realised by interaction of selenium-containing compound with alpha, alpha-dichlorcarboxylic acid, stabilised by nitric acid in amount not more than 5 wt %, and as selenium-containing compound in interaction used is solution of selenious acid in amount 0.5-20.0 wt % and interaction is realised at temperature not higher than 70C. In application of medication for treatment of benign, viral, pre-malignant and malignant non-metastatic skin lesions, dysplastic lesions of visible mucous membranes and other skin lesions, it is applied on lesion nidus on the 1, 2-3, 7-9 and 22-24 days of treatment. ^ EFFECT: medication possesses higher stability and efficiency. ^ 8 cl, 4 ex, 3 tbl
The invention discloses a medicine composition for increasing the bone mineral density and a preparation method thereof. The medicine composition comprises the following components in parts by weight: 45 parts of chondroitin sulfate, 30 parts of calcium carbonate, 10 parts of horny goat weed extract, and 15 parts of glucosum anhydricum. The medicine composition is in form of capsules adopting raw materials homologous with medicine and food as the components. The medicine composition is expected to achieve the effect of increasing the bone mineral density; the chondroitin sulfate, calcium carbonate, horny goat weed extract and glucosum anhydricum are adopted as the main raw materials and scientifically and reasonably processed to prepare the medicine composition. The medicine composition is definite in functions, controllable in quality and safety to take. The preparation method of the medicine composition is simple and can be carried out to prepare the medicine composition by virtue of conventional equipment.
Preclinical studies on pathological pain rely on the von Frey test to examine changes in mechanical thresholds and the acetone spray test to determine alterations in cold sensitivity in rodents. These tests are typically conducted on rodent hindpaws, where animals with pathological pain show reliable nocifensive responses to von Frey filaments and acetone drops applied to the hindpaws. Pathological pain in orofacial regions is also an important clinical problem and has been investigated with rodents. However, performing the von Frey and acetone spray tests in the orofacial region has been challenging, largely due to the high mobility of the head of testing animals. To solve this problem, we implemented a sheltering tube method to assess orofacial nociception in mice. In experiments, mice were sheltered in elevated tubes, where they were well accommodated because the tubes provided safe shelters for mice. Examiners could reliably apply mechanical stimuli with von Frey filament, cold stimuli with acetone spray, and light stimuli with a laser beam to the orofacial regions. We validated this method in Nav1.8-ChR2 mice treated with oxaliplatin that induced peripheral neuropathy. Using the von Frey test, orofacial response frequencies and nociceptive response scores were significantly increased in Nav1.8-ChR2 mice treated with oxaliplatin. In the acetone spray test, the duration of orofacial responses was significantly prolonged in oxaliplatin-treated mice. The response frequencies to laser light stimulation were significantly increased in Nav1.8-ChR2 mice treated with oxaliplatin. Our sheltering tube method allows us to reliably perform the von Frey, acetone spray, and optogenetic tests in orofacial regions to investigate orofacial pain.
The new tert. aromatic alcohols are of formula (I) and their tricarbonyl chromium complexes are of formula (II), in which X is Cl or F and R1, R2 and R3 are H, halogen, opt. substd. alkyl, alkoxy, mono-, di or tri-alkyl silyl, OH, substd. amino or amido, or ester gps. They are made from complexes of formula (III) by alkylation with a benzophenone to produce good yields of complexes (II), which are then de-complexed by action of an oxidising agent to give quantitative yields of alcohols (I). These have applications as pharmaceuticals or agrochemicals and as precursors of triphenyl methane dyes.
The present invention provides pharmacophores for the design, screening and identification of inhibitors of the CYP17a1 enzyme and CYP19a1 enzyme, preferably pharmacophores having the spatial arrangement of atoms as shown in figure 1, wherein: a represents a hydrogen bond acceptor; d represents a hydrogen bond donor; and R represents an aromatic ring. Compounds that conform to the preferred pharmacophores are provided for use as drugs in the treatment of cancer, particularly prostate and breast cancer. By way of example, these compounds include N- (4-ethylphenyl) -5- (2-hydroxy-5-methoxybenzoyl) -2-imino-2H-pyran-3-carboxamide and 2- (4-sulfamoylphenoxy) ethyl 2-amino-3-methylbenzoate. Also provided are methods of treating prostate and breast cancer using the compounds of the invention, and their salts, solvates, hydrates, primary metabolites and prodrugs. Methods of inhibiting CYP17a1 and CYP19a1, and thus inhibiting androgen activity in a subject, are disclosed. The invention also provides methods for designing, screening and identifying compounds that inhibit CYP17a1 and CYP19a 1.
Patients receive methotrexate IV as in arm I on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; pegaspargase IM on day 2, 3, OR 4 of wk 16; oral mercaptopurine daily on wks 5-13, and from wk 24 until the completion of consolidation therapy. Patients also receive IT methotrexate as in arm I on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone 2x daily on weeks 8, 16-18, and 28 for a total of 35 days; vincristine sulfate IV on day 1 of wks 8, 9, 16, 17, 18, 28, and 29; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV over 30 minutes on day 1 of week 20; cytarabine IV or subcutaneously daily on days 2-5 of wks 20 and 21; and oral thioguanine daily on wks 20-21.
Pulmonary hemorrhage can be severe and life-threatening. In children, etiologies of pulmonary hemorrhage include respiratory infection, foreign bodies, bronchiectasis, pulmonary vascular disorders, parenchymal lung disease, and post-surgical complications. Initial management of pulmonary hemorrhage includes stabilization of the patient, securing the airway, initiative high positive end-expiratory pressure to attempt to tamponade the source of hemorrhage and repletion with blood products. Following stabilization of the patient, investigation and further management of hemorrhage includes bronchoscopy, surgery, or catheterization. Sources of bleeding such as endobronchial lesions are often identified and managed with bronchoscopy and the instillation of vasoactive medications or cold water to induce vasospasm and/or balloon tamponade. Vascular bleeding can be surgically ligated or embolized via catheterization. Unidentifiable bleeding occurs with distal vascular injury and is limited to attempted catheter guided embolization of bleeding vessels if found, supportive treatment, and correction of a coagulopathy if present. As etiologies of pulmonary hemorrhage vary, outcomes and prognosis in pediatric pulmonary hemorrhage are difficult to determine, however, mortality still remains a risk.

Tranexamic acid (TXA) is a lysine analog that blocks the conversion of plasminogen to plasmin and the interaction with fibrin, preventing blood clot breakdown, thereby reducing bleeding. The United States (US) Food and Drug Administration approved the intravenous formulation of TXA for the treatment of bleeding patients with hemophilia in 1986 and the oral formulation for the use of severe menorrhagia in 2009. In 2011, The World Health Organization listed TXA as an essential medication based on its successful use in adult trauma-related hemorrhage. Studies show the successful off-label use of TXA in children for congenital heart surgery, orthopedic procedures, neurosurgical procedures, trauma, immune thrombocytopenic purpura, epistaxis, hemorrhage complicating a procedure, bilateral lung transplantation, chemotherapy injections, and bone marrow biopsies among other diagnoses and procedures. Very little data on the use of TXA for pediatric pulmonary hemorrhage exists. Only two case reports show TXA controlling hemoptysis in children with cystic fibrosis-related hemoptysis. A systematic review concluded that the use of TXA for hemoptysis was associated with a significant reduction in length of bleeding. A recent randomized control trial showed the TXA decreased the severity of the hemoptysis and may be used as a bridge to other interventions.

The powerful anti-fibrinolytic properties and relatively low side-effect profile lend TXA to the off-label use in children to reduce bleeding in other diagnoses. There are not enough studies and data, however, to recommend the routine use of TXA in hemoptysis.
Depression is a serious and persistent psychiatric disorder that commonly first manifests during childhood. Depression that starts in childhood is increasing in frequency, likely due both to evolutionary trends and to increased recognition of the disorder. In this umbrella review, we systematically searched the extant literature for genetic, epigenetic, and neurobiological factors that contribute to a childhood onset of depression. We searched PubMed, EMBASE, OVID/PsychInfo, and Google Scholar with the following inclusion criteria: (1) systematic review or meta-analysis from a peer-reviewed journal; (2) inclusion of a measure assessing early age of onset of depression; and (3) assessment of neurobiological, genetic, environmental, and epigenetic predictors of early onset depression. Findings from 89 systematic reviews of moderate to high quality suggest that childhood-onset depressive disorders have neurobiological, genetic, environmental, and epigenetic roots consistent with a diathesis-stress theory of depression. This review identified key putative markers that may be targeted for personalized clinical decision-making and provide important insights concerning candidate mechanisms that might underpin the early onset of depression.
In order to solve the defects of the prior art, the invention provides bone fracture powder with the functions of promoting blood circulation, removing blood stasis, relieving swelling and pain, which is prepared by the following method: s1, preparing medicinal materials. S2, drying the prepared medicinal materials, and crushing the medicinal materials into fine powder according to the formula amount. And S3, sieving and uniformly mixing to obtain the bone fracture powder with the functions of promoting blood circulation, removing blood stasis, relieving swelling and pain. In part by mass, the medicinal materials in step S1 include: 300 portions of large-bonesetting pill 100-. The bone fracture powder prepared by the invention not only has good effect of curing bone fracture, but also has obvious effect of promoting blood circulation, removing blood stasis, relieving swelling and alleviating pain. And is suitable for large-scale production and use, has better curative effect on most people and has high total cure rate.
BACKGROUND: Despite progress in reducing maternal and child mortality worldwide, adverse birth outcomes such as preterm birth, low birth weight (LBW), small for gestational age (SGA), and stillbirth continue to be a major global health challenge. Developing a prediction model for adverse birth outcomes allows for early risk detection and prevention strategies. In this systematic review, we aimed to assess the performance of existing prediction models for adverse birth outcomes and provide a comprehensive summary of their findings.
METHODS: We used the Population, Index prediction model, Comparator, Outcome, Timing, and Setting (PICOTS) approach to retrieve published studies from PubMed/MEDLINE, Scopus, CINAHL, Web of Science, African Journals Online, EMBASE, and Cochrane Library. We used WorldCat, Google, and Google Scholar to find the grey literature. We retrieved data before 1 March 2022. Data were extracted using CHecklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies. We assessed the risk of bias with the Prediction Model Risk of Bias Assessment tool. We descriptively reported the results in tables and graphs.
RESULTS: We included 115 prediction models with the following outcomes: composite adverse birth outcomes (n = 6), LBW (n = 17), SGA (n = 23), preterm birth (n = 71), and stillbirth (n = 9). The sample sizes ranged from composite adverse birth outcomes (n = 32-549), LBW (n = 97-27 233), SGA (n = 41-116 070), preterm birth (n = 31-15 883 784), and stillbirth (n = 180-76 629). Only nine studies were conducted on low- and middle-income countries. 10 studies were externally validated. Risk of bias varied across studies, in which high risk of bias was reported on prediction models for SGA (26.1%), stillbirth (77.8%), preterm birth (31%), LBW (23.5%), and composite adverse birth outcome (33.3%). The area under the receiver operating characteristics curve (AUROC) was the most used metric to describe model performance. The AUROC ranged from 0.51 to 0.83 in studies that reported predictive performance for preterm birth. The AUROC for predicting SGA, LBW, and stillbirth varied from 0.54 to 0.81, 0.60 to 0.84, and 0.65 to 0.72, respectively. Maternal clinical features were the most utilised prognostic markers for preterm and LBW prediction, while uterine artery pulsatility index was used for stillbirth and SGA prediction.
CONCLUSIONS: A varied prognostic factors and heterogeneity between studies were found to predict adverse birth outcomes. Prediction models using consistent prognostic factors, external validation, and adaptation of future risk prediction models for adverse birth outcomes was recommended at different settings.
REGISTRATION: PROSPERO CRD42021281725.
Supported with intensive nursing follow post hospitalization the team of hospital output of the unit to 12 weeks after discharge. These interviews will be conducted at the hospital, at home or by phone and their pace will be adjusted according to the patient's condition. The expected duration of close outpatient follow-up is of maximum 3 months.
Patients with moderate aortic stenosis (AS) have a greater risk of adverse clinical outcomes than that of the general population. How this risk compares with those with severe AS, along with factors associated with outcomes and disease progression, is less clear. We analyzed serial echoes (from 2017 to 2019) from a single healthcare system using Tempus Next (Chicago, Illinois) software. AS severity was defined according to American Heart Association/American College of Cardiology guidelines. Outcomes of interest included death or heart failure hospitalization. We used Cox proportional hazards models and logistic regression to identify predictors of clinical outcome and disease progression, respectively. From 82,805 echoes for 61,546 patients, 1,770; 914; 565; and 1,463 patients had no, mild, moderate, or severe AS, respectively. Both patients with moderate and those with severe AS experienced a similar prevalence of adverse clinical outcomes (p = 0.45) that was significantly greater than that of patients without AS (p <0.01). In patients with moderate AS, atrial fibrillation (hazard ratio 3.29, 95% confidence interval 1.79 to 6.02, p <0.001) and end-stage renal disease (hazard ratio 3.34, 95% confidence interval 1.87 to 5.95, p <0.001) were associated with adverse clinical outcomes. One-third of patients with moderate AS with a subsequent echo (139/434) progressed to severe AS within 1 year. In conclusion, patients with moderate AS can progress rapidly to severe AS and experience a similar risk of adverse clinical outcomes; predictors include atrial fibrillation and low left ventricular ejection fraction. Machine learning algorithms may help identify these patients. Whether these patients may warrant earlier intervention merits further study.
REGONOL ® (pyridostigmine bromide injection, USP) 2 mL single-dose ampule is for intravenous use only. This drug should be administered by or under the supervision of experienced clinicians familiar with the use of agents which reverse or antagonize the effects of neuromuscular blocking agents. Dosage must be individualized in each case. The dosage information which follows is derived from studies based upon units of drug per unit of body weight and is intended to serve as a guide only. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. 

NOTE: CONTAINS BENZYL ALCOHOL (see PRECAUTIONS) 

Reversal doses of REGONOL ® range from 0.1 to 0.25 mg/kg. 5,10,11,12,13 The onset time to peak effect is dose-dependent; return of twitch height to 90% of control occurs within approximately 6 minutes following administration of a 0.25 mg/kg dose of REGONOL ®. 5,12 At lower doses, full recovery usually occurs within 15 minutes in most patients, although others may require a half-hour or more. 

When REGONOL ® is given intravenously to reverse the action of muscle relaxant drugs, it is recommended that atropine sulfate (0.6 to 1.2 mg) or an equipotent dose of glycopyrrolate be given immediately prior to or simultaneously with the administration of REGONOL ®. Side effects, notably excessive secretions and bradycardia are thereby minimized. Please refer to the appropriate prescribing information prior to the use of glycopyrrolate or atropine sulfate. 

To obtain maximum clinical benefits of REGONOL ® and to minimize the possibility of overdosage, the monitoring of muscle twitch response to peripheral nerve stimulation is advised. REGONOL ® should be administered after spontaneous recovery of neuromuscular function has begun. 

Satisfactory reversal can be evident by adequate voluntary respiration, respiratory measurements and use of a peripheral nerve stimulator device. It is recommended that the patient be well-ventilated and a patent airway maintained until complete recovery of normal respiration is assured. Once satisfactory reversal has been attained following administration of REGONOL ®, recurrence of paralysis is unlikely to occur. 

Inadequate reversal of neuromuscular blockade by anticholinesterase drugs is possible with all curariform drugs, and is managed by manual or mechanical ventilation until recovery is judged adequate. The administration of additional doses of anticholinesterase reversal agents is not recommended since excessive dosages of such drugs may produce depolarizing block through their own pharmacological actions.
Composite particles containing metallic shell layers are provided. The particles may include a coating layer, such as of a protective or electrically non-conducting material, over an outermost metallic shell layer. The particle preferably has a plasmon resonance associated with at least one metallic shell layer. The coating layer preferably imparts improved thermal stability to the plasmon resonance. Further, the present invention relates to particles that include at least two metallic shell layers, separated by a coating layer. The addition of a second metallic shell layer preferably allows the plasmon resonance of the shell layer to be more red-shifted with respect to a colloidal particle of the metal that the plasmon resonance of a particle of the same size but with only a single metallic shell.
1. Technical Result Increase in efficiency of treatment of diseases caused by estrogens deficiency.          2. Essence A pharmaceutical composition comprises 2- phenyl- 1-[4- (2-aminoethoxy)benzyl]-Indole of the formula wherein R1-R6, X, Y and n have the values indicated in the description, or its pharmaceutically acceptable salt in pharmaceutically effective amount, one or more estrogens and pharmaceutically acceptable carrier or excipient; the mentioned compound of the formula (I) in combination with other estrogens have the properties same as estrogenic agonists and can be used for treatment of diseases caused by estrogens deficiency, including women's post-climacteric syndrome.           3. Field of Application Medicine.                       Tables: 18
The incidence of MASLD and MASH-associated fibrosis is rapidly increasing worldwide. Drug therapy is hampered by large patient variability and partial representation of human MASH fibrosis in preclinical models. Here, we investigated the mechanisms underlying patient heterogeneity using a discovery dataset and validated in distinct human transcriptomic datasets, to improve patient stratification and translation into subgroup specific patterns. Patient stratification was performed using weighted gene co-expression network analysis (WGCNA) in a large public transcriptomic discovery dataset (n = 216). Differential expression analysis was performed using DESeq2 to obtain differentially expressed genes (DEGs). Ingenuity Pathway analysis was used for functional annotation. The discovery dataset showed relevant fibrosis-related mechanisms representative of disease heterogeneity. Biological complexity embedded in genes signature was used to stratify discovery dataset into six subgroups of various sizes. Of note, subgroup-specific DEGs show differences in directionality in canonical pathways (e.g. Collagen biosynthesis, cytokine signaling) across subgroups. Finally, a multiclass classification model was trained and validated in two datasets. In summary, our work shows a potential alternative for patient population stratification based on heterogeneity in MASLD-MASH mechanisms. Future research is warranted to further characterize patient subgroups and identify protein targets for virtual screening and/or in vitro validation in preclinical models.
Exclusive external radiotherapy. 25Gy in 5 fractions + a 40Gy prostate boost in stereotaxic conditions.